Open·Ingested 91 days ago, not re-verified since

DoW Multiple Sclerosis Clinical Trial Award

Defense Health Agency Contracting Activity - DHACA

Go to the official application

Free. Verify your email, then we send one reminder only.

Download details (file)

Posted: May 5, 2026
Amount: $4,000,000
Closes: Aug 13, 2026 (in 8 days)

Similar opportunities open now

DoW Multiple Sclerosis Early Investigator Research AwardOpenDefense Health Agency Contracting Activity - DHACACloses in 8 days
DoW Multiple Sclerosis Investigator-Initiated Research AwardOpenDefense Health Agency Contracting Activity - DHACACloses in 8 days
DoW Multiple Sclerosis Exploration-Hypothesis Development AwardOpenDefense Health Agency Contracting Activity - DHACACloses in 8 days
DoW Autism Clinical Trial AwardOpenDefense Health Agency Contracting Activity - DHACACloses in 78 days
DoW Arthritis Clinical Research AwardOpenDefense Health Agency Contracting Activity - DHACACloses in 78 days

Classification and identifiers

Solicitation number: HT942526MSRPCTA
Assistance listing (CFDA): 12.420

Amount

$4,000,000

Who can apply

Open to all

About this opportunity

Summary: The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. All applications must address at least one of the FY26 MSRP CTA focus areas. Clinical trials may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Distinctive Features: The FY26 CTA offers two funding levels. The following are generalized descriptions of the scope of research appropriate for each funding level: • Funding Level 1 (CTA-FL1) supports small-scale, proof-of-principle clinical trials (e.g., pilot, first-in-human, phase 0) to ...